Michael Werner
Urology · Harrison, NYNPI 1124340294
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,477 of the $10,705 with a category attached, or 60.5%. 27 manufacturers reported payments, led by Acerus Pharmaceuticals Corporation at 42.9% of the total. Reporting peaked in 2022 at $5,607 and has fallen 88.0% since, to $675 in 2025.
Across 342 payments — averaging $31.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acerus Pharmaceuticals Corporation$5K
- AbbVie$1K
- Bausch Health US, LLC$908
- Endo Pharmaceuticals Inc.$752
- Takeda Pharmaceuticals U.S.A., Inc.$627
- Viiv Healthcare Company$540
- plus $2K from 21 others
What the payments were for
- Consulting fees$3,85036%
- Travel & lodging$3373%
- Food & beverage$6,47761%
- Education$140%
- Other$270%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Acerus Pharmaceuticals Corporation | 11 | $4,590 |
| AbbVie(2 entities) | 91 | $1,439 |
| Bausch Health US, LLC | 51 | $908 |
| Endo Pharmaceuticals Inc. | 50 | $752 |
| Takeda Pharmaceuticals U.S.A., Inc. | 35 | $627 |
| Viiv Healthcare Company | 26 | $540 |
| Gilead | 22 | $439 |
| Antares Pharma, Inc. | 15 | $438 |
| Endo USA, Inc. | 10 | $314 |
| Stryker | 2 | $91 |
| Tolmar, Inc. | 4 | $87 |
| Clarus Therapeutics Inc. | 4 | $64 |
| Boston Scientific | 3 | $61 |
| Lilly USA, LLC | 2 | $47 |
| Sumitomo Pharma America, Inc. | 2 | $41 |
| Idorsia Pharmaceuticals US Inc | 2 | $29 |
| Vitrolife Inc. | 1 | $27 |
| Coloplast | 1 | $27 |
| Ambu Inc. | 2 | $26 |
| Merck | 1 | $24 |
| Evofem Biosciences, Inc. | 1 | $23 |
| OWP Pharmaceuticals, Inc. | 1 | $22 |
| Novo Nordisk | 1 | $21 |
| Kerr Corporation | 1 | $21 |
| Currax Pharmaceuticals LLC | 1 | $17 |
| Therapeuticsmd, Inc. | 1 | $16 |
| Myriad Genetic Laboratories, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,705 in reported general payments places this provider in the 80th percentile of 952 urology providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Testosterone Cypionate | 32 | $1,611 |
| Bupropion XlBupropion Hcl | 20 | $333 |
Paid to pharmacies, not to this prescriber.
Other urology in Harrison
- Peter WalterJamestown$1.9M
- Christopher PieczonkaSyracuse$797K
- Bilal ChughtaiNew York$658K
- Katie MurrayNew York$575K
- Neil BanderNew York$544K
- Robert ValenzuelaNew York$494K
- Jeffrey SpencerCheektowaga$430K
- Kyrollis AttallaNew York$381K
- Benjamin BruckerNew York$364K
- Evan GoldfischerPoughkeepsie$314K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.